Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran.
School of Pharmacy, International Campus, Tehran University of Medical Sciences, Tehran, Iran.
Daru. 2024 Dec;32(2):665-673. doi: 10.1007/s40199-024-00534-x. Epub 2024 Sep 6.
Diabetes mellitus (DM) increases the risk of cardiovascular diseases (CVD) significantly. Statins are recommended for all diabetic patients aged ≥ 40 years to alleviate this risk.
This study aimed to determine the status of the implementation of the recommendations of lipid management strategies for diabetic patients.
In this cross-sectional study, 500 patients with DM, aged ≥ 40 referring to a public pharmacy with at least one diabetic medication in their prescription, were enrolled. Patients' demographics, lipid panel data, medications, personal and family history of atherosclerotic cardiovascular disease (ASCVD), and risk factors for ASCVD were documented. The appropriateness of stain dosing intensity was judged based on the American Diabetes Association (ADA) guideline.
The mean ± SD of the age of patients was 61.39 ± 10.49 years. Among patients, 238 (47.6) were men. More than half of the patients were subject to receiving primary prevention (59.8%, n = 299). For 80.8% (n = 404) of patients, a statin, most frequently atorvastatin (61.8%), was prescribed. The appropriate statin dose based on the guideline for 470 patients (94%), was high-intensity statin. In 70.6% (n = 353) of patients, lipid management was not in accordance with the guideline. Patients with ASCVD were more likely to receive the statins and the appropriate doses compared to patients without ASCVD (p-value < 0.001).
Despite a relatively high percentage of patients who received statins, the lipid management in most patients was not in accordance with the guideline. The profound problem was the suboptimal dosage of statins. Investigating the reasons and barriers of the appropriate management can be helpful. Additionally, since patients without ASCVD who should receive statins for primary prevention were significantly less likely to receive statins and evidence-based doses, more attention is needed for this population.
糖尿病(DM)显著增加心血管疾病(CVD)的风险。建议所有年龄≥40 岁的糖尿病患者使用他汀类药物来降低这种风险。
本研究旨在确定实施糖尿病患者脂质管理策略建议的现状。
在这项横断面研究中,共纳入了 500 名年龄≥40 岁、在处方中至少有一种糖尿病药物的糖尿病患者,他们在一家公共药房就诊。记录了患者的人口统计学数据、血脂谱数据、药物、动脉粥样硬化性心血管疾病(ASCVD)的个人和家族史以及 ASCVD 的危险因素。根据美国糖尿病协会(ADA)指南判断他汀类药物剂量强度的适宜性。
患者的平均年龄±标准差为 61.39±10.49 岁。其中 238 名(47.6%)患者为男性。超过一半的患者(59.8%,n=299)需要接受一级预防。80.8%(n=404)的患者开具了他汀类药物,最常开具的是阿托伐他汀(61.8%)。根据指南,470 名患者(94%)的他汀类药物剂量适宜,为高强度他汀类药物。在 353 名(70.6%)患者中,血脂管理不符合指南。与无 ASCVD 的患者相比,有 ASCVD 的患者更有可能接受他汀类药物和适当剂量的他汀类药物(p 值<0.001)。
尽管接受他汀类药物的患者比例相对较高,但大多数患者的血脂管理不符合指南。突出的问题是他汀类药物的剂量不足。调查适当管理的原因和障碍可能会有所帮助。此外,由于没有 ASCVD 但应该接受他汀类药物进行一级预防的患者接受他汀类药物和基于证据的剂量的可能性明显较低,因此需要更加关注这一人群。